Drug intelligence / Profile preview

HeXell-2020

Development stage: Phase 2
Lead developer: Hexun Biosciences
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intravenous

Overview

HeXell-2020 is an allogenic cell therapy product consisting of umbilical cord-derived mesenchymal stem cells (UCMSCs). Developed by HeXun Biosciences, the drug is designed to leverage the immunomodulatory and regenerative properties of MSCs to treat various conditions, including cardiovascular diseases and age-related frailty. It is currently being evaluated in clinical trials for mild to moderate frailty syndrome in elderly subjects and stable coronary artery disease (CAD), including patients with heart failure. The therapy is administered intravenously and aims to improve clinical outcomes through multilineage differentiation and the secretion of paracrine factors.

Other names: allogenic umbilical cord mesenchymal stem cellsUCMSCs

Beyond the preview

Go deeper on HeXell-2020.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HeXell-2020.

Explore the full profile